Forty out of forty-five. That’s the number of AL amyloidosis patients who have reached a complete response so far in Immix Biopharma’s NEXICART-2 trial. The company’s NXC-201 CAR-T therapy is showing an 89% complete response rate. Four more patients, already MRD-negative, could push that number to 98% if they convert as expected. This is a disease where most treatments fail to keep up. These results are rare.
NXC-201 has not only achieved high response rates but also demonstrated no reported cases of neurotoxicity or enterocolitis across all 45 patients as of the latest update.
Every one of the twenty-five newly enrolled relapsed or refractory AL amyloidosis patients is either in complete response or has already reached MRD negativity. Immix Biopharma’s data show that all MRD-negative patients have hit complete response within a year. No relapses have been seen in any patient who reached either milestone. Four more MRD-negative patients are expected to convert soon. If that happens, the complete response rate will hit 98%—44 out of 45 patients. That’s according to recent RTTNews reporting.
Safety is often the weak spot for CAR-T therapies. Not here. NXC-201 has shown zero cases of neurotoxicity or enterocolitis in all forty-five patients. No exceptions. This clean safety record, paired with the high response rate, puts NXC-201 in a strong position. Few treatments in this space can claim both.
The NEXICART-2 trial enrolled a total of 45 patients, and among those who achieved MRD-negativity, no relapses were observed at the time of the interim analysis. Immix Biopharma has publicly stated its intention to submit a Biologics License Application (BLA) for NXC-201 in 2027, aiming for regulatory approval based on these pivotal results.
The NEXICART-2 trial (NCT06097832) runs across multiple U.S. sites. It is a Phase 2 study with a registrational setup. The therapy uses a sterically-optimized BCMA-targeted CAR-T cell design. NXC-201 includes a proprietary CD3ζ, a CD8 hinge, and a digital filter to cut down on non-specific activation. The FDA has already granted Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy status. NXC-201 also holds Orphan Drug Designation in both the U.S. and EU.
AL amyloidosis is a tough diagnosis. Toxic light chains damage organs and can be fatal. The U.S. population with relapsed or refractory disease is growing by 12% each year. The market could reach $6.6 billion by 2026. Immix Biopharma’s results come as the field looks for treatments that can deliver deep, lasting remissions. Recent reported earlier advances in cell therapy for autoimmune diseases show how fierce the competition is—and how urgent the need for durable options has become.
No relapses among responders. No neurotoxicity. A possible 98% complete response rate. NXC-201 is changing the outlook for AL amyloidosis. If these results hold at final readout, Immix Biopharma could set a new standard for both efficacy and safety. The bar just got higher for next-generation cell therapies.
